ClinicalTrials.gg
CompletedNCT01500187Updated Oct 2, 2024Results posted

Fluoride Varnish for Treatment of White Spot Lesions

An interventional study of Vanish Varnish and Pediagel in White Spot Lesions, sponsored by Solventum US LLC. Completed at 1 site in United States. Open to participants aged 12 Years to 16 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-10-02.

Sponsored by Solventum US LLC · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
38
Allocation
Randomized
Ages
12 Years to 16 Years
Sex
All
01

Study summary

Study will look at ability of fluoride varnish to remineralize white spot enamel lesions that can occur around the edge of fixed orthodontic brackets.

Read the detailed description

To determine the efficacy of 5% sodium fluoride varnish with tricalcium phosphate in reverting white spot lesions after fixed orthodontic treatment, compared with a fluoride gel.

02

Conditions studied

  • White Spot Lesions

Keywords

  • white spot lesions
  • fixed orthodontic brackets
  • fluoride varnish
  • fluoride gel
03

In context

Lead sponsor

Solventum US LLC is the lead sponsor of 64 studies on the registry; 2 are open to participants now.

Of its 18 completed or terminated interventional studies of FDA-regulated products, 16 (89%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
12 Years to 16 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • no systemic disease
  • has completed fixed orthodontic treatment, brackets debonded
  • has at least two teeth with whitre spot lesions
  • has received conventional periodontal therapy after orthodontic tretament

Exclusion criteria

Exclusion Criteria:

  • presence of enamel hypoplasia or dental fluorosis
  • presence of tetracycline pigmentation
  • periodontal pocketing of 3mm or greater
  • taking antibiotics
  • presence of carious cavities
  • allergy to fluoride gel / varnish being used in study
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
38 participants (actual)

Study arms

  • Active comparator
    Pediagel

    1.23% Acidulated Phosphate Fluoride Gel

    Device: Pediagel

  • Experimental
    3M Vanish Varnish

    5% sodium fluoride varnish

    Device: Vanish Varnish

Interventions

  • DeviceVanish Varnish

    5% sodium fluoride varnish with tricalcium phosphate

  • DevicePediagel

    1.23% Acidulated Phosphate Fluoride Gel

06

What researchers measure

Primary outcomes

  1. DIAGNOdent Readings at Baseline, Three and Six Months - Intergroup Comparison

    Outcome of fluoride varnish or gel application to white spot lesions as measured by DIAGNOdent device after orthodontic debonding. Values shown represent the mean DIAGNOdent reading. The DIAGNOdent scale spans values from 0 to 30+ where larger values indicate higher levels of demineralization.

    Time frame: Baseline, Three and Six Month

07

Results

Posted Feb 26, 2019

Participant flow

Participant flow — Overall Study
MilestonePediagelVanish Varnish
Started2315
Completed1715
Not completed60
Withdrew: Lost to follow-up60

Outcome measures

PrimaryDIAGNOdent Readings at Baseline, Three and Six Months - Intergroup Comparison

Outcome of fluoride varnish or gel application to white spot lesions as measured by DIAGNOdent device after orthodontic debonding. Values shown represent the mean DIAGNOdent reading. The DIAGNOdent scale spans values from 0 to 30+ where larger values indicate higher levels of demineralization.

Time frame:
Baseline, Three and Six Month
Reported as:
Mean · units on a scale
DIAGNOdent Readings at Baseline, Three and Six Months - Intergroup Comparison
units on a scalePediagelVanish Varnish
Baseline5.10 ± 2.676.01 ± 4.17
Three Months4.08 ± 2.325.50 ± 3.81
Six Months3.52 ± 2.463.95 ± 2.97
Statistical analysis
  • Pediagel vs Vanish Varnish · ANOVA · p = 0.636
  • Pediagel vs Vanish Varnish · ANOVA · p = 0.001
  • Pediagel vs Vanish Varnish · ANOVA · p = 0.423

Adverse events

Collected over Six Months. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Group 20/19 (0%)0/19 (0%)0/19 (0%)
Group 10/19 (0%)0/19 (0%)0/19 (0%)

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)PediagelVanish VarnishTotal
<=18 years231538
Between 18 and 65 years000
>=65 years000
Sex: Female, Male
Sex: Female, Male(Participants)PediagelVanish VarnishTotal
Female11819
Male12719
08

Study locations

1 site
  • College of Dentistry
    Memphis, Tennessee 38163, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2012, a primary completion of Mar 2014 and a completion of Mar 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2019, 4 years 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 22, 2011
First posted
Dec 28, 2011
Start
Feb 2012
Primary completionActual
Mar 31, 2014
CompletionActual
Mar 31, 2014
Results first posted
Feb 26, 2019
Last update
Oct 2, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 2, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01500187
Lead sponsor
Solventum US LLC
Collaborators
University of Tennessee, 3M
Responsible party
Sponsor
First posted
Dec 28, 2011
Start date
Feb 2012
Primary completion
Mar 31, 2014
Completion
Mar 31, 2014
Results posted
Feb 26, 2019
Last update
Oct 2, 2024

Study contacts

Franklin Garcia-Godoy, DDS, MS
principal investigator · University of Tennessee

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion